nodes	percent_of_prediction	percent_of_DWPC	metapath
Droperidol—Fenbufen—PTGS1—breast cancer	0.00393	0.21	CrCbGaD
Droperidol—Cardiac arrest—Fluorouracil—breast cancer	0.00247	0.00324	CcSEcCtD
Droperidol—Body temperature increased—Exemestane—breast cancer	0.00246	0.00322	CcSEcCtD
Droperidol—Somnolence—Letrozole—breast cancer	0.00246	0.00322	CcSEcCtD
Droperidol—Somnolence—Anastrozole—breast cancer	0.00246	0.00322	CcSEcCtD
Droperidol—Rash—Lapatinib—breast cancer	0.00246	0.00322	CcSEcCtD
Droperidol—Dermatitis—Lapatinib—breast cancer	0.00246	0.00322	CcSEcCtD
Droperidol—Hyperglycaemia—Thiotepa—breast cancer	0.00245	0.00321	CcSEcCtD
Droperidol—Angioedema—Chlorambucil—breast cancer	0.00238	0.00312	CcSEcCtD
Droperidol—Dizziness—Fulvestrant—breast cancer	0.00237	0.0031	CcSEcCtD
Droperidol—Ventricular arrhythmia—Epirubicin—breast cancer	0.00236	0.00309	CcSEcCtD
Droperidol—Dizziness—Toremifene—breast cancer	0.00234	0.00306	CcSEcCtD
Droperidol—Body temperature increased—Ixabepilone—breast cancer	0.00232	0.00304	CcSEcCtD
Droperidol—Hypersensitivity—Exemestane—breast cancer	0.00229	0.003	CcSEcCtD
Droperidol—Chills—Goserelin—breast cancer	0.00228	0.00299	CcSEcCtD
Droperidol—Rash—Fulvestrant—breast cancer	0.00226	0.00296	CcSEcCtD
Droperidol—Dermatitis—Fulvestrant—breast cancer	0.00226	0.00296	CcSEcCtD
Droperidol—Bronchospasm—Gemcitabine—breast cancer	0.00225	0.00295	CcSEcCtD
Droperidol—Fenbufen—PTGS2—breast cancer	0.00225	0.12	CrCbGaD
Droperidol—Rash—Toremifene—breast cancer	0.00223	0.00292	CcSEcCtD
Droperidol—Dermatitis—Toremifene—breast cancer	0.00223	0.00292	CcSEcCtD
Droperidol—Body temperature increased—Anastrozole—breast cancer	0.00219	0.00286	CcSEcCtD
Droperidol—Body temperature increased—Letrozole—breast cancer	0.00219	0.00286	CcSEcCtD
Droperidol—Ventricular arrhythmia—Doxorubicin—breast cancer	0.00218	0.00286	CcSEcCtD
Droperidol—Hallucination—Thiotepa—breast cancer	0.00217	0.00284	CcSEcCtD
Droperidol—Hypersensitivity—Ixabepilone—breast cancer	0.00216	0.00284	CcSEcCtD
Droperidol—Angioedema—Tamoxifen—breast cancer	0.00212	0.00278	CcSEcCtD
Droperidol—Hyperglycaemia—Mitoxantrone—breast cancer	0.00212	0.00278	CcSEcCtD
Droperidol—Cardiac arrest—Paclitaxel—breast cancer	0.00211	0.00276	CcSEcCtD
Droperidol—Drowsiness—Mitoxantrone—breast cancer	0.00209	0.00274	CcSEcCtD
Droperidol—Body temperature increased—Raloxifene—breast cancer	0.00208	0.00272	CcSEcCtD
Droperidol—Body temperature increased—Idarubicin—breast cancer	0.00208	0.00272	CcSEcCtD
Droperidol—Hyperglycaemia—Gemcitabine—breast cancer	0.00206	0.0027	CcSEcCtD
Droperidol—Hypertension—Vinblastine—breast cancer	0.00206	0.0027	CcSEcCtD
Droperidol—Dizziness—Exemestane—breast cancer	0.00206	0.0027	CcSEcCtD
Droperidol—Hypersensitivity—Anastrozole—breast cancer	0.00204	0.00267	CcSEcCtD
Droperidol—Hypertension—Tamoxifen—breast cancer	0.002	0.00262	CcSEcCtD
Droperidol—Amenorrhoea—Epirubicin—breast cancer	0.00199	0.0026	CcSEcCtD
Droperidol—Anxiety—Tamoxifen—breast cancer	0.00197	0.00258	CcSEcCtD
Droperidol—Rash—Exemestane—breast cancer	0.00196	0.00257	CcSEcCtD
Droperidol—Dermatitis—Exemestane—breast cancer	0.00196	0.00257	CcSEcCtD
Droperidol—Palpitations—Goserelin—breast cancer	0.00196	0.00256	CcSEcCtD
Droperidol—Chills—Thiotepa—breast cancer	0.00195	0.00256	CcSEcCtD
Droperidol—Dizziness—Ixabepilone—breast cancer	0.00194	0.00254	CcSEcCtD
Droperidol—Hypersensitivity—Idarubicin—breast cancer	0.00193	0.00253	CcSEcCtD
Droperidol—Hypertension—Goserelin—breast cancer	0.00191	0.00251	CcSEcCtD
Droperidol—Anxiety—Goserelin—breast cancer	0.00188	0.00246	CcSEcCtD
Droperidol—Anaphylactic shock—Melphalan—breast cancer	0.00185	0.00243	CcSEcCtD
Droperidol—Rash—Ixabepilone—breast cancer	0.00185	0.00243	CcSEcCtD
Droperidol—Dermatitis—Ixabepilone—breast cancer	0.00185	0.00242	CcSEcCtD
Droperidol—Amenorrhoea—Doxorubicin—breast cancer	0.00184	0.00241	CcSEcCtD
Droperidol—Dizziness—Anastrozole—breast cancer	0.00183	0.0024	CcSEcCtD
Droperidol—Dizziness—Letrozole—breast cancer	0.00183	0.0024	CcSEcCtD
Droperidol—Angioedema—Vinorelbine—breast cancer	0.00181	0.00237	CcSEcCtD
Droperidol—Tachycardia—Melphalan—breast cancer	0.00181	0.00237	CcSEcCtD
Droperidol—Anaphylactic shock—Goserelin—breast cancer	0.00181	0.00237	CcSEcCtD
Droperidol—Shock—Goserelin—breast cancer	0.00178	0.00233	CcSEcCtD
Droperidol—Tachycardia—Goserelin—breast cancer	0.00176	0.00231	CcSEcCtD
Droperidol—Palpitations—Vinorelbine—breast cancer	0.00175	0.0023	CcSEcCtD
Droperidol—Ventricular tachycardia—Epirubicin—breast cancer	0.00175	0.00229	CcSEcCtD
Droperidol—Rash—Letrozole—breast cancer	0.00174	0.00228	CcSEcCtD
Droperidol—Rash—Anastrozole—breast cancer	0.00174	0.00228	CcSEcCtD
Droperidol—Dermatitis—Letrozole—breast cancer	0.00174	0.00228	CcSEcCtD
Droperidol—Dermatitis—Anastrozole—breast cancer	0.00174	0.00228	CcSEcCtD
Droperidol—Dizziness—Raloxifene—breast cancer	0.00174	0.00227	CcSEcCtD
Droperidol—Hypotension—Melphalan—breast cancer	0.00173	0.00227	CcSEcCtD
Droperidol—Cardiac arrest—Capecitabine—breast cancer	0.00173	0.00227	CcSEcCtD
Droperidol—Hyperglycaemia—Paclitaxel—breast cancer	0.00173	0.00226	CcSEcCtD
Droperidol—Hypertension—Vinorelbine—breast cancer	0.00171	0.00224	CcSEcCtD
Droperidol—Depression—Paclitaxel—breast cancer	0.0017	0.00223	CcSEcCtD
Droperidol—Hypotension—Goserelin—breast cancer	0.00169	0.00221	CcSEcCtD
Droperidol—Chills—Mitoxantrone—breast cancer	0.00169	0.00221	CcSEcCtD
Droperidol—Chills—Irinotecan—breast cancer	0.00169	0.00221	CcSEcCtD
Droperidol—Body temperature increased—Chlorambucil—breast cancer	0.00168	0.0022	CcSEcCtD
Droperidol—Gynaecomastia—Methotrexate—breast cancer	0.00167	0.00219	CcSEcCtD
Droperidol—Haloperidol—CYP1A1—breast cancer	0.00167	0.0891	CrCbGaD
Droperidol—Rash—Raloxifene—breast cancer	0.00166	0.00217	CcSEcCtD
Droperidol—Rash—Idarubicin—breast cancer	0.00166	0.00217	CcSEcCtD
Droperidol—Dermatitis—Raloxifene—breast cancer	0.00165	0.00217	CcSEcCtD
Droperidol—Dermatitis—Idarubicin—breast cancer	0.00165	0.00217	CcSEcCtD
Droperidol—Chills—Gemcitabine—breast cancer	0.00164	0.00215	CcSEcCtD
Droperidol—Hypertension—Thiotepa—breast cancer	0.00164	0.00214	CcSEcCtD
Droperidol—Domperidone—CYP2D6—breast cancer	0.00163	0.0869	CrCbGaD
Droperidol—Anaphylactic shock—Vinorelbine—breast cancer	0.00162	0.00212	CcSEcCtD
Droperidol—Ventricular tachycardia—Doxorubicin—breast cancer	0.00162	0.00212	CcSEcCtD
Droperidol—Anxiety—Thiotepa—breast cancer	0.00161	0.00211	CcSEcCtD
Droperidol—Somnolence—Goserelin—breast cancer	0.00161	0.00211	CcSEcCtD
Droperidol—Bronchospasm—Docetaxel—breast cancer	0.0016	0.00209	CcSEcCtD
Droperidol—Tachycardia—Vinorelbine—breast cancer	0.00158	0.00207	CcSEcCtD
Droperidol—Hypersensitivity—Chlorambucil—breast cancer	0.00157	0.00205	CcSEcCtD
Droperidol—Bronchospasm—Capecitabine—breast cancer	0.00155	0.00203	CcSEcCtD
Droperidol—Hypotension—Vinorelbine—breast cancer	0.00151	0.00198	CcSEcCtD
Droperidol—Tachycardia—Thiotepa—breast cancer	0.00151	0.00198	CcSEcCtD
Droperidol—Syncope—Irinotecan—breast cancer	0.00147	0.00192	CcSEcCtD
Droperidol—Loss of consciousness—Irinotecan—breast cancer	0.00144	0.00188	CcSEcCtD
Droperidol—Hypersensitivity—Vinblastine—breast cancer	0.00144	0.00188	CcSEcCtD
Droperidol—Body temperature increased—Goserelin—breast cancer	0.00143	0.00187	CcSEcCtD
Droperidol—Hyperglycaemia—Capecitabine—breast cancer	0.00142	0.00186	CcSEcCtD
Droperidol—Hypertension—Mitoxantrone—breast cancer	0.00141	0.00185	CcSEcCtD
Droperidol—Hypertension—Irinotecan—breast cancer	0.00141	0.00185	CcSEcCtD
Droperidol—Depression—Capecitabine—breast cancer	0.0014	0.00183	CcSEcCtD
Droperidol—Domperidone—CYP3A4—breast cancer	0.00139	0.0746	CrCbGaD
Droperidol—Hypersensitivity—Tamoxifen—breast cancer	0.00139	0.00183	CcSEcCtD
Droperidol—Anxiety—Mitoxantrone—breast cancer	0.00139	0.00182	CcSEcCtD
Droperidol—Hypertension—Gemcitabine—breast cancer	0.00138	0.0018	CcSEcCtD
Droperidol—Chills—Paclitaxel—breast cancer	0.00138	0.0018	CcSEcCtD
Droperidol—Somnolence—Thiotepa—breast cancer	0.00137	0.0018	CcSEcCtD
Droperidol—Hypersensitivity—Melphalan—breast cancer	0.00137	0.00179	CcSEcCtD
Droperidol—Pimozide—CYP2D6—breast cancer	0.00136	0.0726	CrCbGaD
Droperidol—Anaphylactic shock—Mitoxantrone—breast cancer	0.00134	0.00175	CcSEcCtD
Droperidol—Anaphylactic shock—Irinotecan—breast cancer	0.00134	0.00175	CcSEcCtD
Droperidol—Hypersensitivity—Goserelin—breast cancer	0.00133	0.00174	CcSEcCtD
Droperidol—Shock—Mitoxantrone—breast cancer	0.00131	0.00172	CcSEcCtD
Droperidol—Shock—Irinotecan—breast cancer	0.00131	0.00172	CcSEcCtD
Droperidol—Tachycardia—Mitoxantrone—breast cancer	0.0013	0.00171	CcSEcCtD
Droperidol—Anaphylactic shock—Gemcitabine—breast cancer	0.0013	0.0017	CcSEcCtD
Droperidol—Dizziness—Vinblastine—breast cancer	0.00129	0.00169	CcSEcCtD
Droperidol—Body temperature increased—Vinorelbine—breast cancer	0.00128	0.00168	CcSEcCtD
Droperidol—Anaphylactic shock—Fluorouracil—breast cancer	0.00128	0.00168	CcSEcCtD
Droperidol—Dizziness—Tamoxifen—breast cancer	0.00125	0.00164	CcSEcCtD
Droperidol—Tachycardia—Fluorouracil—breast cancer	0.00125	0.00164	CcSEcCtD
Droperidol—Hypotension—Mitoxantrone—breast cancer	0.00125	0.00163	CcSEcCtD
Droperidol—Hypotension—Irinotecan—breast cancer	0.00125	0.00163	CcSEcCtD
Droperidol—Haloperidol—CYP2D6—breast cancer	0.00124	0.0663	CrCbGaD
Droperidol—Body temperature increased—Thiotepa—breast cancer	0.00122	0.0016	CcSEcCtD
Droperidol—Angioedema—Paclitaxel—breast cancer	0.00122	0.0016	CcSEcCtD
Droperidol—Hypotension—Gemcitabine—breast cancer	0.00122	0.00159	CcSEcCtD
Droperidol—Cardiac arrest—Epirubicin—breast cancer	0.0012	0.00158	CcSEcCtD
Droperidol—Syncope—Paclitaxel—breast cancer	0.0012	0.00157	CcSEcCtD
Droperidol—Dizziness—Goserelin—breast cancer	0.0012	0.00157	CcSEcCtD
Droperidol—Hypotension—Fluorouracil—breast cancer	0.0012	0.00157	CcSEcCtD
Droperidol—Rash—Tamoxifen—breast cancer	0.00119	0.00156	CcSEcCtD
Droperidol—Hypersensitivity—Vinorelbine—breast cancer	0.00119	0.00156	CcSEcCtD
Droperidol—Dermatitis—Tamoxifen—breast cancer	0.00119	0.00156	CcSEcCtD
Droperidol—Somnolence—Mitoxantrone—breast cancer	0.00119	0.00156	CcSEcCtD
Droperidol—Somnolence—Irinotecan—breast cancer	0.00119	0.00156	CcSEcCtD
Droperidol—Palpitations—Paclitaxel—breast cancer	0.00118	0.00154	CcSEcCtD
Droperidol—Loss of consciousness—Paclitaxel—breast cancer	0.00117	0.00154	CcSEcCtD
Droperidol—Rash—Melphalan—breast cancer	0.00117	0.00153	CcSEcCtD
Droperidol—Dermatitis—Melphalan—breast cancer	0.00117	0.00153	CcSEcCtD
Droperidol—Chills—Docetaxel—breast cancer	0.00117	0.00153	CcSEcCtD
Droperidol—Pimozide—CYP3A4—breast cancer	0.00117	0.0623	CrCbGaD
Droperidol—Domperidone—ABCB1—breast cancer	0.00116	0.0621	CrCbGaD
Droperidol—Somnolence—Gemcitabine—breast cancer	0.00116	0.00152	CcSEcCtD
Droperidol—Hypertension—Paclitaxel—breast cancer	0.00115	0.00151	CcSEcCtD
Droperidol—Rash—Goserelin—breast cancer	0.00114	0.00149	CcSEcCtD
Droperidol—Hypersensitivity—Thiotepa—breast cancer	0.00114	0.00149	CcSEcCtD
Droperidol—Dermatitis—Goserelin—breast cancer	0.00114	0.00149	CcSEcCtD
Droperidol—Somnolence—Fluorouracil—breast cancer	0.00114	0.00149	CcSEcCtD
Droperidol—Anxiety—Paclitaxel—breast cancer	0.00113	0.00148	CcSEcCtD
Droperidol—Chills—Capecitabine—breast cancer	0.00113	0.00148	CcSEcCtD
Droperidol—Cardiac arrest—Doxorubicin—breast cancer	0.00111	0.00146	CcSEcCtD
Droperidol—Anaphylactic shock—Paclitaxel—breast cancer	0.00109	0.00143	CcSEcCtD
Droperidol—Shock—Paclitaxel—breast cancer	0.00107	0.0014	CcSEcCtD
Droperidol—Dizziness—Vinorelbine—breast cancer	0.00107	0.0014	CcSEcCtD
Droperidol—Haloperidol—CYP3A4—breast cancer	0.00106	0.0569	CrCbGaD
Droperidol—Tachycardia—Paclitaxel—breast cancer	0.00106	0.00139	CcSEcCtD
Droperidol—Body temperature increased—Mitoxantrone—breast cancer	0.00106	0.00138	CcSEcCtD
Droperidol—Body temperature increased—Irinotecan—breast cancer	0.00106	0.00138	CcSEcCtD
Droperidol—Drowsiness—Methotrexate—breast cancer	0.00104	0.00137	CcSEcCtD
Droperidol—Depression—Methotrexate—breast cancer	0.00104	0.00136	CcSEcCtD
Droperidol—Body temperature increased—Gemcitabine—breast cancer	0.00103	0.00135	CcSEcCtD
Droperidol—Dizziness—Thiotepa—breast cancer	0.00102	0.00134	CcSEcCtD
Droperidol—Rash—Vinorelbine—breast cancer	0.00102	0.00134	CcSEcCtD
Droperidol—Dermatitis—Vinorelbine—breast cancer	0.00102	0.00134	CcSEcCtD
Droperidol—Hypotension—Paclitaxel—breast cancer	0.00102	0.00133	CcSEcCtD
Droperidol—Syncope—Docetaxel—breast cancer	0.00101	0.00133	CcSEcCtD
Droperidol—Body temperature increased—Fluorouracil—breast cancer	0.00101	0.00132	CcSEcCtD
Droperidol—Palpitations—Docetaxel—breast cancer	0.001	0.00131	CcSEcCtD
Droperidol—Loss of consciousness—Docetaxel—breast cancer	0.000994	0.0013	CcSEcCtD
Droperidol—Hyperglycaemia—Epirubicin—breast cancer	0.000988	0.00129	CcSEcCtD
Droperidol—Hypersensitivity—Mitoxantrone—breast cancer	0.000984	0.00129	CcSEcCtD
Droperidol—Hypersensitivity—Irinotecan—breast cancer	0.000984	0.00129	CcSEcCtD
Droperidol—Syncope—Capecitabine—breast cancer	0.000982	0.00129	CcSEcCtD
Droperidol—Hypertension—Docetaxel—breast cancer	0.000977	0.00128	CcSEcCtD
Droperidol—Drowsiness—Epirubicin—breast cancer	0.000976	0.00128	CcSEcCtD
Droperidol—Rash—Thiotepa—breast cancer	0.000975	0.00128	CcSEcCtD
Droperidol—Dermatitis—Thiotepa—breast cancer	0.000974	0.00128	CcSEcCtD
Droperidol—Pimozide—ABCB1—breast cancer	0.00097	0.0518	CrCbGaD
Droperidol—Somnolence—Paclitaxel—breast cancer	0.000968	0.00127	CcSEcCtD
Droperidol—Palpitations—Capecitabine—breast cancer	0.000968	0.00127	CcSEcCtD
Droperidol—Loss of consciousness—Capecitabine—breast cancer	0.000963	0.00126	CcSEcCtD
Droperidol—Hypertension—Capecitabine—breast cancer	0.000946	0.00124	CcSEcCtD
Droperidol—Hypersensitivity—Fluorouracil—breast cancer	0.000942	0.00123	CcSEcCtD
Droperidol—Anxiety—Capecitabine—breast cancer	0.000929	0.00122	CcSEcCtD
Droperidol—Anaphylactic shock—Docetaxel—breast cancer	0.000923	0.00121	CcSEcCtD
Droperidol—Hyperglycaemia—Doxorubicin—breast cancer	0.000914	0.0012	CcSEcCtD
Droperidol—Shock—Docetaxel—breast cancer	0.000908	0.00119	CcSEcCtD
Droperidol—Drowsiness—Doxorubicin—breast cancer	0.000903	0.00118	CcSEcCtD
Droperidol—Tachycardia—Docetaxel—breast cancer	0.000901	0.00118	CcSEcCtD
Droperidol—Haloperidol—ABCB1—breast cancer	0.000885	0.0473	CrCbGaD
Droperidol—Dizziness—Irinotecan—breast cancer	0.000883	0.00116	CcSEcCtD
Droperidol—Shock—Capecitabine—breast cancer	0.000879	0.00115	CcSEcCtD
Droperidol—Tachycardia—Capecitabine—breast cancer	0.000872	0.00114	CcSEcCtD
Droperidol—Hypotension—Docetaxel—breast cancer	0.000863	0.00113	CcSEcCtD
Droperidol—Body temperature increased—Paclitaxel—breast cancer	0.000861	0.00113	CcSEcCtD
Droperidol—Dizziness—Fluorouracil—breast cancer	0.000846	0.00111	CcSEcCtD
Droperidol—Rash—Mitoxantrone—breast cancer	0.000842	0.0011	CcSEcCtD
Droperidol—Rash—Irinotecan—breast cancer	0.000842	0.0011	CcSEcCtD
Droperidol—Dermatitis—Irinotecan—breast cancer	0.000841	0.0011	CcSEcCtD
Droperidol—Dermatitis—Mitoxantrone—breast cancer	0.000841	0.0011	CcSEcCtD
Droperidol—Chills—Methotrexate—breast cancer	0.00084	0.0011	CcSEcCtD
Droperidol—Hypotension—Capecitabine—breast cancer	0.000835	0.00109	CcSEcCtD
Droperidol—Somnolence—Docetaxel—breast cancer	0.000821	0.00108	CcSEcCtD
Droperidol—Rash—Gemcitabine—breast cancer	0.00082	0.00107	CcSEcCtD
Droperidol—Dermatitis—Gemcitabine—breast cancer	0.00082	0.00107	CcSEcCtD
Droperidol—Rash—Fluorouracil—breast cancer	0.000807	0.00106	CcSEcCtD
Droperidol—Dermatitis—Fluorouracil—breast cancer	0.000806	0.00106	CcSEcCtD
Droperidol—Hypersensitivity—Paclitaxel—breast cancer	0.000802	0.00105	CcSEcCtD
Droperidol—Chills—Epirubicin—breast cancer	0.000786	0.00103	CcSEcCtD
Droperidol—Body temperature increased—Docetaxel—breast cancer	0.00073	0.000956	CcSEcCtD
Droperidol—Chills—Doxorubicin—breast cancer	0.000728	0.000953	CcSEcCtD
Droperidol—Dizziness—Paclitaxel—breast cancer	0.00072	0.000944	CcSEcCtD
Droperidol—Body temperature increased—Capecitabine—breast cancer	0.000707	0.000926	CcSEcCtD
Droperidol—Rash—Paclitaxel—breast cancer	0.000687	0.0009	CcSEcCtD
Droperidol—Dermatitis—Paclitaxel—breast cancer	0.000686	0.000899	CcSEcCtD
Droperidol—Syncope—Epirubicin—breast cancer	0.000684	0.000896	CcSEcCtD
Droperidol—Hypersensitivity—Docetaxel—breast cancer	0.00068	0.000891	CcSEcCtD
Droperidol—Palpitations—Epirubicin—breast cancer	0.000674	0.000883	CcSEcCtD
Droperidol—Loss of consciousness—Epirubicin—breast cancer	0.000671	0.000878	CcSEcCtD
Droperidol—Anaphylactic shock—Methotrexate—breast cancer	0.000665	0.000872	CcSEcCtD
Droperidol—Hypertension—Epirubicin—breast cancer	0.000659	0.000863	CcSEcCtD
Droperidol—Hypersensitivity—Capecitabine—breast cancer	0.000659	0.000863	CcSEcCtD
Droperidol—Anxiety—Epirubicin—breast cancer	0.000647	0.000848	CcSEcCtD
Droperidol—Syncope—Doxorubicin—breast cancer	0.000633	0.000829	CcSEcCtD
Droperidol—Palpitations—Doxorubicin—breast cancer	0.000624	0.000817	CcSEcCtD
Droperidol—Anaphylactic shock—Epirubicin—breast cancer	0.000623	0.000816	CcSEcCtD
Droperidol—Hypotension—Methotrexate—breast cancer	0.000622	0.000814	CcSEcCtD
Droperidol—Loss of consciousness—Doxorubicin—breast cancer	0.000621	0.000813	CcSEcCtD
Droperidol—Shock—Epirubicin—breast cancer	0.000613	0.000803	CcSEcCtD
Droperidol—Dizziness—Docetaxel—breast cancer	0.000611	0.0008	CcSEcCtD
Droperidol—Hypertension—Doxorubicin—breast cancer	0.00061	0.000798	CcSEcCtD
Droperidol—Tachycardia—Epirubicin—breast cancer	0.000608	0.000796	CcSEcCtD
Droperidol—Anxiety—Doxorubicin—breast cancer	0.000599	0.000785	CcSEcCtD
Droperidol—Somnolence—Methotrexate—breast cancer	0.000592	0.000775	CcSEcCtD
Droperidol—Dizziness—Capecitabine—breast cancer	0.000591	0.000774	CcSEcCtD
Droperidol—Rash—Docetaxel—breast cancer	0.000582	0.000763	CcSEcCtD
Droperidol—Hypotension—Epirubicin—breast cancer	0.000582	0.000762	CcSEcCtD
Droperidol—Dermatitis—Docetaxel—breast cancer	0.000582	0.000762	CcSEcCtD
Droperidol—Anaphylactic shock—Doxorubicin—breast cancer	0.000576	0.000755	CcSEcCtD
Droperidol—Shock—Doxorubicin—breast cancer	0.000567	0.000743	CcSEcCtD
Droperidol—Rash—Capecitabine—breast cancer	0.000564	0.000738	CcSEcCtD
Droperidol—Dermatitis—Capecitabine—breast cancer	0.000563	0.000738	CcSEcCtD
Droperidol—Tachycardia—Doxorubicin—breast cancer	0.000562	0.000737	CcSEcCtD
Droperidol—Somnolence—Epirubicin—breast cancer	0.000554	0.000725	CcSEcCtD
Droperidol—Hypotension—Doxorubicin—breast cancer	0.000538	0.000705	CcSEcCtD
Droperidol—Body temperature increased—Methotrexate—breast cancer	0.000526	0.000689	CcSEcCtD
Droperidol—Somnolence—Doxorubicin—breast cancer	0.000512	0.000671	CcSEcCtD
Droperidol—Body temperature increased—Epirubicin—breast cancer	0.000492	0.000645	CcSEcCtD
Droperidol—Hypersensitivity—Methotrexate—breast cancer	0.00049	0.000642	CcSEcCtD
Droperidol—Hypersensitivity—Epirubicin—breast cancer	0.000459	0.000601	CcSEcCtD
Droperidol—Body temperature increased—Doxorubicin—breast cancer	0.000455	0.000597	CcSEcCtD
Droperidol—Dizziness—Methotrexate—breast cancer	0.00044	0.000576	CcSEcCtD
Droperidol—Hypersensitivity—Doxorubicin—breast cancer	0.000425	0.000556	CcSEcCtD
Droperidol—Rash—Methotrexate—breast cancer	0.00042	0.00055	CcSEcCtD
Droperidol—Dermatitis—Methotrexate—breast cancer	0.000419	0.000549	CcSEcCtD
Droperidol—Dizziness—Epirubicin—breast cancer	0.000412	0.000539	CcSEcCtD
Droperidol—Rash—Epirubicin—breast cancer	0.000393	0.000514	CcSEcCtD
Droperidol—Dermatitis—Epirubicin—breast cancer	0.000392	0.000514	CcSEcCtD
Droperidol—Dizziness—Doxorubicin—breast cancer	0.000381	0.000499	CcSEcCtD
Droperidol—Rash—Doxorubicin—breast cancer	0.000363	0.000476	CcSEcCtD
Droperidol—Dermatitis—Doxorubicin—breast cancer	0.000363	0.000475	CcSEcCtD
Droperidol—ADRA1A—Signaling Pathways—PDGFA—breast cancer	4.47e-05	0.000205	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—ERBB4—breast cancer	4.47e-05	0.000205	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MMP3—breast cancer	4.47e-05	0.000205	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—STAT5A—breast cancer	4.47e-05	0.000205	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—PIK3CB—breast cancer	4.46e-05	0.000205	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—ITPR1—breast cancer	4.43e-05	0.000203	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—TGFBR2—breast cancer	4.41e-05	0.000202	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—ERBB4—breast cancer	4.4e-05	0.000202	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—STAT5A—breast cancer	4.4e-05	0.000202	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MMP3—breast cancer	4.4e-05	0.000202	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—PIK3CB—breast cancer	4.39e-05	0.000201	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—ITPR1—breast cancer	4.34e-05	0.000199	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—SMAD4—breast cancer	4.33e-05	0.000199	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—STAT5A—breast cancer	4.31e-05	0.000198	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MMP3—breast cancer	4.31e-05	0.000198	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—ERBB4—breast cancer	4.31e-05	0.000198	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IGF1R—breast cancer	4.3e-05	0.000198	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—PIK3CB—breast cancer	4.3e-05	0.000197	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—CXCL8—breast cancer	4.28e-05	0.000197	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—SMAD4—breast cancer	4.26e-05	0.000196	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IGF1R—breast cancer	4.23e-05	0.000194	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—HES1—breast cancer	4.23e-05	0.000194	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—CXCL8—breast cancer	4.22e-05	0.000193	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—NCOR1—breast cancer	4.2e-05	0.000193	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PLA2G4A—breast cancer	4.2e-05	0.000193	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—SMAD4—breast cancer	4.17e-05	0.000191	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—HES1—breast cancer	4.16e-05	0.000191	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—FGF1—breast cancer	4.16e-05	0.000191	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CSF2—breast cancer	4.16e-05	0.000191	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—RAF1—breast cancer	4.15e-05	0.00019	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IGF1R—breast cancer	4.15e-05	0.00019	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—NCOR1—breast cancer	4.14e-05	0.00019	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PLA2G4A—breast cancer	4.14e-05	0.00019	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—CXCL8—breast cancer	4.13e-05	0.000189	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—NRG1—breast cancer	4.13e-05	0.000189	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—H2AFX—breast cancer	4.1e-05	0.000188	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—IL2—breast cancer	4.09e-05	0.000188	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—FGF1—breast cancer	4.09e-05	0.000188	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CSF2—breast cancer	4.09e-05	0.000188	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—RAF1—breast cancer	4.08e-05	0.000187	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—HES1—breast cancer	4.07e-05	0.000187	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—E2F1—breast cancer	4.07e-05	0.000187	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—NRG1—breast cancer	4.06e-05	0.000186	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PLA2G4A—breast cancer	4.05e-05	0.000186	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—NCOR1—breast cancer	4.05e-05	0.000186	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—PIK3CB—breast cancer	4.05e-05	0.000186	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—H2AFX—breast cancer	4.03e-05	0.000185	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—IL2—breast cancer	4.03e-05	0.000185	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CSF2—breast cancer	4e-05	0.000184	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—FGF1—breast cancer	4e-05	0.000184	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—E2F1—breast cancer	4e-05	0.000184	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—RAF1—breast cancer	4e-05	0.000183	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—PIK3CB—breast cancer	3.98e-05	0.000183	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—NRG1—breast cancer	3.98e-05	0.000182	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—H2AFX—breast cancer	3.95e-05	0.000181	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—IL2—breast cancer	3.94e-05	0.000181	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—E2F1—breast cancer	3.92e-05	0.00018	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—SPP1—breast cancer	3.91e-05	0.000179	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—PIK3CB—breast cancer	3.9e-05	0.000179	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—CXCL8—breast cancer	3.89e-05	0.000179	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—ERBB3—breast cancer	3.87e-05	0.000177	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—FGFR2—breast cancer	3.86e-05	0.000177	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—SPP1—breast cancer	3.85e-05	0.000176	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—CXCL8—breast cancer	3.83e-05	0.000176	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—ERBB3—breast cancer	3.8e-05	0.000175	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—FGFR2—breast cancer	3.8e-05	0.000174	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—SPP1—breast cancer	3.76e-05	0.000173	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—CXCL8—breast cancer	3.75e-05	0.000172	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—ERBB3—breast cancer	3.72e-05	0.000171	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—FGFR2—breast cancer	3.72e-05	0.000171	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—IL2—breast cancer	3.72e-05	0.000171	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—TERT—breast cancer	3.7e-05	0.00017	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—IL2—breast cancer	3.66e-05	0.000168	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—TERT—breast cancer	3.65e-05	0.000167	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—FGFR1—breast cancer	3.6e-05	0.000165	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—IL2—breast cancer	3.58e-05	0.000164	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—TERT—breast cancer	3.57e-05	0.000164	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—HIF1A—breast cancer	3.54e-05	0.000163	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—FGFR1—breast cancer	3.54e-05	0.000162	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—HIF1A—breast cancer	3.49e-05	0.00016	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—FGFR1—breast cancer	3.47e-05	0.000159	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—LEP—breast cancer	3.46e-05	0.000159	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CAV1—breast cancer	3.43e-05	0.000157	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—HIF1A—breast cancer	3.41e-05	0.000157	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—LEP—breast cancer	3.4e-05	0.000156	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—KDR—breast cancer	3.39e-05	0.000155	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CAV1—breast cancer	3.37e-05	0.000155	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—KDR—breast cancer	3.33e-05	0.000153	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—LEP—breast cancer	3.33e-05	0.000153	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—ESR1—breast cancer	3.3e-05	0.000152	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CAV1—breast cancer	3.3e-05	0.000152	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—KDR—breast cancer	3.26e-05	0.00015	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—FN1—breast cancer	3.26e-05	0.00015	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—ESR1—breast cancer	3.25e-05	0.000149	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—NFKBIA—breast cancer	3.22e-05	0.000148	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—FN1—breast cancer	3.21e-05	0.000147	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—NOTCH1—breast cancer	3.19e-05	0.000146	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—ESR1—breast cancer	3.18e-05	0.000146	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—NFKBIA—breast cancer	3.17e-05	0.000146	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—FN1—breast cancer	3.14e-05	0.000144	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—NOTCH1—breast cancer	3.14e-05	0.000144	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—APC—breast cancer	3.12e-05	0.000143	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—KIT—breast cancer	3.12e-05	0.000143	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PIK3CG—breast cancer	3.12e-05	0.000143	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—NFKBIA—breast cancer	3.1e-05	0.000142	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—EGF—breast cancer	3.09e-05	0.000142	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—NOTCH1—breast cancer	3.08e-05	0.000141	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PIK3CG—breast cancer	3.07e-05	0.000141	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—KIT—breast cancer	3.07e-05	0.000141	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—APC—breast cancer	3.07e-05	0.000141	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—EGF—breast cancer	3.04e-05	0.000139	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—APC—breast cancer	3.01e-05	0.000138	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—KIT—breast cancer	3.01e-05	0.000138	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PIK3CG—breast cancer	3.01e-05	0.000138	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—MAPK3—breast cancer	2.99e-05	0.000137	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—EGF—breast cancer	2.97e-05	0.000136	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—MAPK3—breast cancer	2.94e-05	0.000135	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—BRAF—breast cancer	2.93e-05	0.000135	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—BRAF—breast cancer	2.89e-05	0.000132	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—MAPK3—breast cancer	2.88e-05	0.000132	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IGF1—breast cancer	2.86e-05	0.000131	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—AKT2—breast cancer	2.86e-05	0.000131	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—EGFR—breast cancer	2.84e-05	0.000131	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—BRAF—breast cancer	2.83e-05	0.00013	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IGF1—breast cancer	2.81e-05	0.000129	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—AKT2—breast cancer	2.81e-05	0.000129	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—EGFR—breast cancer	2.8e-05	0.000128	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IGF1—breast cancer	2.75e-05	0.000126	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—AKT2—breast cancer	2.75e-05	0.000126	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PIK3CD—breast cancer	2.74e-05	0.000126	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—EGFR—breast cancer	2.74e-05	0.000126	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—PIK3CA—breast cancer	2.72e-05	0.000125	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—SERPINE1—breast cancer	2.71e-05	0.000125	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PIK3CD—breast cancer	2.7e-05	0.000124	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—KRAS—breast cancer	2.69e-05	0.000123	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—PIK3CA—breast cancer	2.67e-05	0.000123	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—SERPINE1—breast cancer	2.67e-05	0.000123	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PIK3CD—breast cancer	2.64e-05	0.000121	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—KRAS—breast cancer	2.64e-05	0.000121	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—PIK3CA—breast cancer	2.62e-05	0.00012	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—SERPINE1—breast cancer	2.61e-05	0.00012	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—NOS3—breast cancer	2.59e-05	0.000119	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—KRAS—breast cancer	2.59e-05	0.000119	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—NOS3—breast cancer	2.55e-05	0.000117	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—NOS3—breast cancer	2.5e-05	0.000115	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—PIK3CA—breast cancer	2.47e-05	0.000113	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MDM2—breast cancer	2.46e-05	0.000113	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—RAF1—breast cancer	2.45e-05	0.000112	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—RELA—breast cancer	2.44e-05	0.000112	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—PIK3CA—breast cancer	2.43e-05	0.000111	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—ERBB2—breast cancer	2.42e-05	0.000111	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MDM2—breast cancer	2.42e-05	0.000111	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—RAF1—breast cancer	2.41e-05	0.000111	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—RELA—breast cancer	2.4e-05	0.00011	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PIK3CB—breast cancer	2.39e-05	0.00011	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MTOR—breast cancer	2.39e-05	0.00011	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—ERBB2—breast cancer	2.38e-05	0.000109	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—PIK3CA—breast cancer	2.38e-05	0.000109	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MDM2—breast cancer	2.37e-05	0.000109	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—RAF1—breast cancer	2.36e-05	0.000108	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PIK3CB—breast cancer	2.35e-05	0.000108	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MTOR—breast cancer	2.35e-05	0.000108	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—RELA—breast cancer	2.35e-05	0.000108	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—ERBB2—breast cancer	2.33e-05	0.000107	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PIK3CB—breast cancer	2.3e-05	0.000106	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MTOR—breast cancer	2.3e-05	0.000106	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CXCL8—breast cancer	2.3e-05	0.000105	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—HRAS—breast cancer	2.28e-05	0.000105	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CXCL8—breast cancer	2.26e-05	0.000104	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—HRAS—breast cancer	2.25e-05	0.000103	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CDKN1B—breast cancer	2.24e-05	0.000103	CbGpPWpGaD
Droperidol—DRD2—GPCR downstream signaling—AKT1—breast cancer	2.22e-05	0.000102	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CXCL8—breast cancer	2.21e-05	0.000102	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CDKN1B—breast cancer	2.21e-05	0.000101	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—HRAS—breast cancer	2.2e-05	0.000101	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CASP3—breast cancer	2.2e-05	0.000101	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IL2—breast cancer	2.2e-05	0.000101	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—IL6—breast cancer	2.19e-05	0.0001	CbGpPWpGaD
Droperidol—HTR2A—GPCR downstream signaling—AKT1—breast cancer	2.18e-05	0.0001	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CASP3—breast cancer	2.16e-05	9.93e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	2.16e-05	9.92e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IL2—breast cancer	2.16e-05	9.92e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—IL6—breast cancer	2.15e-05	9.87e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CCND1—breast cancer	2.14e-05	9.83e-05	CbGpPWpGaD
Droperidol—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	2.14e-05	9.82e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—JUN—breast cancer	2.14e-05	9.81e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CTNNB1—breast cancer	2.12e-05	9.73e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CASP3—breast cancer	2.12e-05	9.73e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IL2—breast cancer	2.12e-05	9.71e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CCND1—breast cancer	2.11e-05	9.67e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—IL6—breast cancer	2.11e-05	9.66e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—JUN—breast cancer	2.1e-05	9.65e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CTNNB1—breast cancer	2.09e-05	9.57e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MMP9—breast cancer	2.08e-05	9.54e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—CDKN1A—breast cancer	2.07e-05	9.51e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PTEN—breast cancer	2.07e-05	9.48e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CCND1—breast cancer	2.06e-05	9.47e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—JUN—breast cancer	2.06e-05	9.45e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MMP9—breast cancer	2.05e-05	9.39e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	2.04e-05	9.38e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—CDKN1A—breast cancer	2.04e-05	9.35e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PTEN—breast cancer	2.03e-05	9.33e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MAPK8—breast cancer	2.02e-05	9.28e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling by GPCR—AKT1—breast cancer	2.02e-05	9.25e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MMP9—breast cancer	2e-05	9.19e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	2e-05	9.16e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PTEN—breast cancer	1.99e-05	9.14e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MAPK8—breast cancer	1.99e-05	9.13e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling by GPCR—AKT1—breast cancer	1.98e-05	9.1e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MAPK8—breast cancer	1.95e-05	8.94e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling by GPCR—AKT1—breast cancer	1.94e-05	8.91e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—SRC—breast cancer	1.92e-05	8.8e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—SRC—breast cancer	1.89e-05	8.65e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—VEGFA—breast cancer	1.87e-05	8.57e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—STAT3—breast cancer	1.85e-05	8.48e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—SRC—breast cancer	1.85e-05	8.47e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—VEGFA—breast cancer	1.84e-05	8.43e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—STAT3—breast cancer	1.82e-05	8.35e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—VEGFA—breast cancer	1.8e-05	8.25e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—STAT3—breast cancer	1.78e-05	8.17e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MAPK3—breast cancer	1.77e-05	8.1e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MAPK3—breast cancer	1.74e-05	7.97e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—MYC—breast cancer	1.72e-05	7.88e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—TGFB1—breast cancer	1.71e-05	7.86e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MAPK3—breast cancer	1.7e-05	7.81e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—MYC—breast cancer	1.69e-05	7.76e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—TGFB1—breast cancer	1.69e-05	7.74e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—EGFR—breast cancer	1.68e-05	7.71e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—MYC—breast cancer	1.65e-05	7.59e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—EGFR—breast cancer	1.65e-05	7.59e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—TGFB1—breast cancer	1.65e-05	7.58e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—EGFR—breast cancer	1.62e-05	7.43e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—KRAS—breast cancer	1.59e-05	7.28e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—KRAS—breast cancer	1.56e-05	7.17e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—KRAS—breast cancer	1.53e-05	7.02e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—PIK3CA—breast cancer	1.46e-05	6.69e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—PIK3CA—breast cancer	1.43e-05	6.58e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—TP53—breast cancer	1.41e-05	6.47e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	1.4e-05	6.45e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—TP53—breast cancer	1.39e-05	6.37e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—TP53—breast cancer	1.36e-05	6.24e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—HRAS—breast cancer	1.35e-05	6.19e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—HRAS—breast cancer	1.33e-05	6.09e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—HRAS—breast cancer	1.3e-05	5.96e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—IL6—breast cancer	1.29e-05	5.92e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—IL6—breast cancer	1.27e-05	5.83e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—IL6—breast cancer	1.24e-05	5.71e-05	CbGpPWpGaD
Droperidol—DRD2—Signaling Pathways—AKT1—breast cancer	1.19e-05	5.47e-05	CbGpPWpGaD
Droperidol—HTR2A—Signaling Pathways—AKT1—breast cancer	1.17e-05	5.38e-05	CbGpPWpGaD
Droperidol—ADRA1A—Signaling Pathways—AKT1—breast cancer	1.15e-05	5.27e-05	CbGpPWpGaD
